This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Verve Therapeutics Stock (NASDAQ:VERV) 30 days 90 days 365 days Advanced Chart Get Verve Therapeutics alerts:Sign Up Key Stats Today's Range$11.13▼$11.1350-Day Range$10.91▼$11.3852-Week Range$2.86▼$11.40VolumeN/AAverage Volume3.94 million shsMarket Capitalization$992.13 millionP/E RatioN/ADividend YieldN/APrice Target$14.57Consensus RatingHold Company Overview Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Read More Verve Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreVERV MarketRank™: Verve Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 495th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingVerve Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageVerve Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verve Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VERV. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for VERV. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Verve Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verve Therapeutics' insider trading history. Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERV Stock News HeadlinesAnalysts Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $14.57August 25, 2025 | americanbankingnews.comCanaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)August 9, 2025 | theglobeandmail.comNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do… | Brownstone Research (Ad)Verve Therapeutics Announces Merger and Nasdaq DelistingAugust 3, 2025 | theglobeandmail.comVerve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102July 29, 2025 | msn.comEli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 26, 2025 | finanznachrichten.deEli Lilly completes acquisition of Verve TherapeuticsJuly 25, 2025 | msn.comLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 25, 2025 | prnewswire.comSee More Headlines VERV Stock Analysis - Frequently Asked Questions How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.36. The company earned $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 35.81% and a negative net margin of 303.64%. When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO. Who are Verve Therapeutics' major shareholders? Top institutional shareholders of Verve Therapeutics include Alphabet Inc. (13.65%), Alpine Associates Management Inc. (3.07%), Hudson Bay Capital Management LP and Hudson Bay Capital Management LP. Insiders that own company stock include Krishna Yeshwant, Andrew D Ashe, Sekar Kathiresan, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv. View institutional ownership trends. What other stocks do shareholders of Verve Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2025Today8/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERV CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Verve Therapeutics$14.57 High Price Target$24.00 Low Price Target$11.00 Potential Upside/Downside+30.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.71 million Net Margins-303.64% Pretax Margin-303.10% Return on Equity-35.81% Return on Assets-27.57% Debt Debt-to-Equity RatioN/A Current Ratio9.84 Quick Ratio9.84 Sales & Book Value Annual Sales$32.33 million Price / Sales30.69 Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book1.91Miscellaneous Outstanding Shares89,140,000Free Float71,938,000Market Cap$992.13 million OptionableOptionable Beta2.23 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VERV) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.